Tafalgie Therapeutics :

A Novel Pharmaceutical Approach to Pain Treatment

Our project

Tafalgie Therapeutics is an early-stage Biotech company focusing on the development of next-generation analgesics.

Tafalgie Therapeutics is a spin-off from the CNRS / Aix-Marseille University IBDM laboratory specializing in the development of next-generation pain-relieving peptides without the disabling adverse effects of opioids. It was set up following the discovery of a novel mechanism of action for the analgesic effect of a secreted endogenous protein, TAFA4, based on modulation of the pain signal between the peripheral sensory neurons and the central nervous system.

The future first-in-class analgesic peptides developed by Tafalgie Therapeutics should be able to relieve and prevent acute and chronic pain, with no loss of efficacy over time and with far fewer adverse effects than are observed for most currently used anagesics (e.g., anxiety, respiratory problems, dizziness).

These peptides should clearly act as disease modifiers capable of blocking the mechanisms of pain initiation.


Key Achievements
Key Achievements

Latest News


All Team
Visit our contact page